Trial Profile
Prospective randomized controlled trial Comparing Peg-IFN alpha-2a monotherapy versus Peg-IFN alpha-2a +ribavirin combination therapy after curative ablation for HCV-positive Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 23 Jan 2015 Planned End Date changed from 1 May 2016 to 31 May 2016 as reported by University Hospital Medical Information Network - Japan.
- 11 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.